Literature DB >> 12947327

Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer.

Masayuki Koizumi1, Ryuichiro Doi, Eiji Toyoda, Toshihiko Masui, Sidhartha S Tulachan, Yoshiya Kawaguchi, Koji Fujimoto, George K Gittes, Masayuki Imamura.   

Abstract

BACKGROUND: During pancreatic development, pancreatic duodenal homeobox gene-1 (PDX-1) is expressed in pancreatic duct cells that have the potential to differentiate into islets. Therefore, PDX-1 is thought to be a marker of de-differentiated cells with the capacity to redifferentiate into several pancreatic cell types. We analyzed PDX-1 expression in human pancreatic cancer specimens, pancreatic cancer cell lines, and the effects of forced expression of PDX-1 in pancreatic cancer cells.
METHODS: Thirty-five pancreatic adenocarcinomas were immunohistochemically stained with a polyclonal rabbit antibody against mouse PDX-1. Correlations with tumor characteristics were made with chi-squared analysis. The influence of clinicopathologic factors on survival was assessed. The expression of PDX-1 in pancreatic cancer cells was examined. Replication-deficient recombinant adenoviruses were constructed by the cosmid-adenoviral DNA terminal protein complex method. PANC-1 cells were infected with Ad-pdx-1 or Ad-LacZ. PANC-1 cells that were infected with adenovirus were used in a cell growth assay and a migration assay and for morphologic analysis.
RESULTS: Interestingly, 43% of pancreatic cancers were positive for PDX-1 expression, and 57% of pancreatic cancers were negative (normal pancreatic exocrine tissue shows little or no staining for PDX-1). Lymph node metastasis (P =.02) and histologic grade (P =.04) were correlated significantly with PDX-1 expression. Patients with positive PDX-1 had a significantly worse prognosis than those patients with negative PDX-1 (P =.02). Importantly, PDX-1 was an independent variable that effected overall survival (P =.03). Pancreatic cancer cell lines showed no PDX-1 expression. There were no significant differences in cell proliferation or morphologic condition between Ad-pdx-1- and Ad-lacZ-infected PANC-1 cells. However, Ad-pdx-1-infected PANC-1 cells did show a significantly higher migration rate than Ad-lacZ-infected PANC-1 cells.
CONCLUSIONS: Re-expression of PDX-1 may represent a return to a more de-differentiated state by more aggressive pancreatic cancers and may also represent an important new tumor marker for these aggressive cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947327     DOI: 10.1067/msy.2003.231

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  27 in total

1.  Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5.

Authors:  Guisheng Zhou; Shi-He Liu; Kelly M Shahi; Hua Wang; Xueyan Duan; Xia Lin; Xin-Hua Feng; Min Li; William E Fisher; Francesco J Demayo; David Dawson; F Charles Brunicardi
Journal:  Mol Endocrinol       Date:  2012-06-05

2.  Metformin Restrains Pancreatic Duodenal Homeobox-1 (PDX-1) Function by Inhibiting ERK Signaling in Pancreatic Ductal Adenocarcinoma.

Authors:  G Zhou; J Yu; A Wang; S-H Liu; J Sinnett-Smith; J Wu; R Sanchez; J Nemunaitis; C Ricordi; E Rozengurt; F C Brunicardi
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

3.  Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation.

Authors:  Takeshi Miyatsuka; Hideaki Kaneto; Toshihiko Shiraiwa; Taka-aki Matsuoka; Kaoru Yamamoto; Ken Kato; Yumiko Nakamura; Shizuo Akira; Kiyoshi Takeda; Yoshitaka Kajimoto; Yoshimitsu Yamasaki; Eric P Sandgren; Yoshiya Kawaguchi; Christopher V E Wright; Yoshio Fujitani
Journal:  Genes Dev       Date:  2006-06-01       Impact factor: 11.361

Review 4.  Defining the cancer master switch.

Authors:  Courtney J Balentine; David H Berger; Shi-He Liu; Changyi Chen; John Nemunaitis; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

5.  Intra- and interobserver reproducibility of interpretation of immunohistochemical stains of prostate cancer.

Authors:  Sara Jonmarker Jaraj; Philippe Camparo; Helen Boyle; François Germain; Bo Nilsson; Fredrik Petersson; Lars Egevad
Journal:  Virchows Arch       Date:  2009-09-18       Impact factor: 4.064

6.  Pancreatic ductal morphogenesis and the Pdx1 homeodomain transcription factor.

Authors:  Melanie P Wescott; Meritxell Rovira; Maximilian Reichert; Johannes von Burstin; Anna Means; Steven D Leach; Anil K Rustgi
Journal:  Mol Biol Cell       Date:  2009-09-30       Impact factor: 4.138

Review 7.  Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform.

Authors:  J Wu; S Liu; J Yu; G Zhou; D Rao; C M Jay; P Kumar; R Sanchez; N Templeton; N Senzer; P Maples; J Nemunaitis; F C Brunicardi
Journal:  Cancer Gene Ther       Date:  2014-01-24       Impact factor: 5.987

8.  EZH2 couples pancreatic regeneration to neoplastic progression.

Authors:  Jon Mallen-St Clair; Rengin Soydaner-Azeloglu; Kyoung Eun Lee; Laura Taylor; Alexandra Livanos; Yuliya Pylayeva-Gupta; George Miller; Raphaël Margueron; Danny Reinberg; Dafna Bar-Sagi
Journal:  Genes Dev       Date:  2012-03-01       Impact factor: 11.361

Review 9.  Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.

Authors:  Thomas S Frank; Xiaotian Sun; Yuqing Zhang; Jingxuan Yang; William E Fisher; Marie-Claude Gingras; Min Li
Journal:  Cancer Lett       Date:  2015-04-15       Impact factor: 8.679

10.  Transcription factor PDX-1 in human colorectal adenocarcinoma: a potential tumor marker?

Authors:  Nikiforos Ballian; Shi-He Liu; Francis-Charles Brunicardi
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.